{"id":"W2529603678","doi":"10.1200/jco.2012.30.15_suppl.8013","title":"Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Bortezomib; Dosing; Urology; Multiple myeloma; Internal medicine; Clinical endpoint; Gastroenterology; Pharmacology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00119244,0.002032876,0.00212669,0.0006001347,0.0005439272,0.0009122569,0.001069298,0.00146501,0.005628004],"category_scores_gemma":[0.0005816236,0.0007955969,0.000900635,0.0004513524,0.0009219741,0.0006568829,0.0004774691,0.002760045,0.00156127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000961594,"about_ca_system_score_gemma":0.001621637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001009089,"about_ca_topic_score_gemma":0.002495347,"domain_scores_codex":[0.9996796,0.0001267256,0.00001799379,0.00004821022,0.00003203955,0.0000955073],"domain_scores_gemma":[0.9994887,0.00006259174,0.00008972354,0.00003199002,0.00002435837,0.0003026763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7476624,0.07275877,0.005819341,0.001138175,0.0009675455,0.0005793503,0.0003409769,0.002490911,0.04115625,0.0005142365,0.006416547,0.1201554],"study_design_scores_gemma":[0.6061664,0.3770473,0.007564199,0.00006413599,0.0002384926,0.0003378462,0.0000415499,0.0008890257,0.003223884,0.000190612,0.004215251,0.000021332],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842492,0.00307866,0.0005818847,0.0009020837,0.0002634876,0.005386003,0.001470975,0.0001918669,0.003875794],"genre_scores_gemma":[0.9797122,0.002411687,0.00150672,0.001635325,0.0002532267,0.004455414,0.003516834,0.00004094553,0.006467651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005628004,"threshold_uncertainty_score":0.0188275,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2079971987066957,"score_gpt":0.5220809802286622,"score_spread":0.3140837815219666,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}